Research Topics
Species | Robert M CaliffSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010Robert M Califf
Duke Translational Medicine Institute, 200 Trent Dr, 1117 Davison Bldg, Durham, NC 27710, USA
JAMA 307:1838-47. 2012..Strengthened reporting requirements for studies registered with ClinicalTrials.gov enable a comprehensive evaluation of the national trials portfolio...
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessmentRobert M Califf
Duke Translational Medicine Institute, Durham, NC 27715, USA
Pharmacoepidemiol Drug Saf 17:782-6. 2008
Linking scientific discovery and better health for the nation: the first three years of the NIH's Clinical and Translational Science AwardsRobert M Califf
Duke Translational Medicine Institute, Durham, North Carolina 27710, USA
Acad Med 85:457-62. 2010....
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiativeRajendra H Mehta
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Arch Intern Med 166:2027-34. 2006..We sought to determine recent trends in adherence to guideline-based therapies for NSTE ACS...
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials)Abdallah G Rebeiz
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 95:611-4. 2005..7% vs 48.0% with >/=50% ST-segment resolution, p = 0.03) and sustained over 180 minutes after drug administration; this transient benefit may suggest a time frame when more optimal percutaneous coronary intervention can be performed...
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery diseaseSvati H Shah
Division of Cardiovascular Medicine, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Am Heart J 163:844-850.e1. 2012..Cardiovascular risk models remain incomplete. Small-molecule metabolites may reflect underlying disease and, as such, serve as novel biomarkers of cardiovascular risk...
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)Shelby D Reed
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Am Heart J 150:323-9. 2005..The difference will be smaller or nonexistent in settings where brand-name ACE inhibitors are prescribed...
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Durham, NC 27715, USA
J Gen Intern Med 23:310-6. 2008..Despite advances in pharmacologic therapy and invasive management strategies for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), these patients still suffer substantial morbidity and mortality...
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] ReJonathan P Piccini
Division of Cardiology, Department of Medicine, and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am J Cardiol 102:1427-32. 2008..Unfortunately, beta blockers were underused acutely in patients with sustained VT/VF...
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatmentLynda A Szczech
Renal Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Kidney Int 77:239-46. 2010..These differential outcomes underscore the need for dedicated trials in these subpopulations...
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarctionJonathan P Piccini
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Crit Care Med 39:78-83. 2011..The objective of this analysis was to describe the survival of patients with sustained ventricular tachycardia/ventricular fibrillation after myocardial infarction according to antiarrhythmic drug treatment...
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromesSunil V Rao
The Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 96:1200-6. 2005..Therapies that minimize bleeding risk and maintain an anticoagulant effect may improve outcomes among patients who have ACS...
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapyTrip J Meine
Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
Am Heart J 149:670-4. 2005..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy...
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trialShelby D Reed
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 152:500-8. 2006..Our findings have implications not only for care of patients but also for the conduct of international trials...
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trialsRajendra H Mehta
Duke Clinical Research Institute, Durham, NC 27715, USA
J Interv Cardiol 20:299-306. 2007..Adverse events occur following non-ST elevation acute coronary syndromes (NSTE ACS). However, the timing of these events in relation to index event is less clear...
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trialMelvin R Echols
Duke Clinical Research Institute, Durham, North Carolina 27705, USA
J Card Fail 12:684-8. 2006..Although unadjusted clinical outcomes are better for African Americans presenting with ADHF, these differences diminished after adjustment for baseline characteristics...
Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitalsMatthew T Roe
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 156:185-92. 2008....
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgeryRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, DUMC Box 3850, Durham, NC 27705, USA
Circulation 125:749-56. 2012..In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angiography 12 to 18 months after coronary artery bypass graft surgery, and subsequent clinical outcomes...
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary diseaseMark Y Chan
Duke Clinical Research Institute, Durham, North Carolina, USA
JACC Cardiovasc Interv 1:369-78. 2008..We sought to characterize the utilization and impact of a conservative medical management strategy for patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) and significant coronary artery disease on early angiography...
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)Robert M Califf
Duke Translational Medicine Institute, Durham, North Carolina, USA
Am J Cardiol 104:151-7. 2009..In conclusion, no evidence was found of adverse interactions between the angiotensin-receptor blocker valsartan and beta blockers or of a negative effect of the combination of valsartan, captopril, and beta blockers...
Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research studyYee Weng Wong
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
Circ Heart Fail 6:203-10. 2013..However, predictors associated with the increased risk of incident HF have not been well characterized. We aimed to identify independent predictors of incident HF hospitalization among patients with impaired glucose tolerance...
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trialJonathan P Piccini
Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
Eur Heart J 31:211-21. 2010..To determine whether predictors of sudden cardiac death (SCD) vary with time after myocardial infarction (MI)...
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarctionRajendra H Mehta
Duke Clinical Research Institute, Durham, NC, USA
Am J Med 119:70.e1-8. 2006..Accordingly, the current study examines the relationship of African American race to patient-related clinical factors, angiographic findings, and clinical events...
Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trialRajendra H Mehta
Duke Clinical Research Institute, Box 17969, Durham, NC 27715, USA
Circulation 124:280-8. 2011....
Relationship between depressive symptoms and long-term mortality in patients with heart failureWei Jiang
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Am Heart J 154:102-8. 2007..The study sought to assess the association of depressive symptoms and long-term mortality of patients with HF and to explore the prognostic predictability of the Beck Depression Inventory (BDI) scale for patients with HF...
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graftRajendra H Mehta
Division of Cardiology, Department of Internal Medicine, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA
Circulation 114:I396-401. 2006..The influence of an internal mammary artery (IMA) graft on long-term outcomes after percutaneous saphenous vein graft (SVG) intervention is currently unknown...
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trialsPierluigi Tricoci
Duke Clinical Research Institute, Durham, NC 27715, USA
Circ Cardiovasc Qual Outcomes 4:448-58. 2011..We systematically reviewed the effect of upstream GP IIb/IIIa inhibitor use in NSTE ACS as reported in published clinical trials...
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysisRajendra H Mehta
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 109:320-6. 2012..These data highlight the importance of understanding factors associated with gender-related differences in bleeding and represent an opportunity for improving outcomes of women and men with fibrinolytic-treated STEMI...
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgeryRenato D Lopes
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
N Engl J Med 361:235-44. 2009....
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromesSunil V Rao
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
J Am Coll Cardiol 47:809-16. 2006..The goal of this study was to determine the association between Thrombolysis In Myocardial Infarction (TIMI) and Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleeding and clinical outcomes...
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci
Duke Clinical Research Institute, 2400 Pratt St, Room 0311 Terrace Level, Durham, NC 27705, USA
Circulation 116:2669-77. 2007..We evaluated the relationship between time from hospital admission to coronary angiography and outcomes in high-risk patients with non-ST-segment-elevation acute coronary syndrome who underwent angiography within 48 hours of admission...
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonJonathan P Piccini
MHS, Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27710
Circulation 127:224-32. 2013..We sought to define the factors associated with the occurrence of stroke and systemic embolism in a large, international atrial fibrillation (AF) trial...
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year resultsRenato D Lopes
Duke Clinical Research Institute, Durham, NC, USA
Am Heart J 164:379-386.e1. 2012..We compared the 5-year clinical outcomes of patients in PREVENT IV treated with edifoligide and placebo to identify predictors of long-term clinical outcomes...
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndromeHassan Kassem-Moussa
Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 148:439-46. 2004..CONCLUSIONS: In patients stabilized after presenting with a spectrum of ACS and treated with sibrafiban and/or aspirin, stroke occurred in fewer than 1% within 90 days but carried a significant mortality and morbidity risk...
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY LibraryJohn L Petersen
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 148:269-76. 2004..It is hoped that the SYNERGY Library will serve as a model for future substudy design to maximize academic insight within the framework of a large-scale, multicenter trial...
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trialsJohn M Galla
Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 151:16-24. 2006..All patients with ACS should have CK-MB measurement to search for cardiac ischemia. Patients with elevated CK-MB should receive aggressive management commensurate with their increased risks...
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarctionManesh R Patel
Duke Clinical Research Institute, Durham, NC 27715, USA
Am Heart J 151:316-22. 2006..Time from symptom onset to treatment strongly predicted the development of tamponade, underscoring the need for continued efforts to increase speed to treatment in acute MI...
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 294:2594-600. 2005....
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research DatabaseJohn L Petersen
Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA
Am Heart J 159:462-470.e1. 2010..Relationships between long-term use and level of dual antiplatelet therapy and outcomes after drug-eluting stent implantation are not well established...
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policyGillian D Sanders
Duke Clinical Research Institute, Duke Medical Center, Durham, NC 27715, USA
Am Heart J 153:951-9. 2007....
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantationEric L Eisenstein
Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
JAMA 297:159-68. 2007..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
Is rhythm-control superior to rate-control in patients with atrial fibrillation and diastolic heart failure?Melissa H Kong
Duke Clinical Research Institute, Durham, NC, USA
Ann Noninvasive Electrocardiol 15:209-17. 2010..We aimed to determine whether patients with AF and heart failure with preserved ejection fraction (EF) survive longer with rhythm versus rate-control strategy...
The impact of postrandomization crossover of therapy in acute coronary syndromes careKenneth W Mahaffey
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Circ Cardiovasc Qual Outcomes 4:211-9. 2011..Using SYNERGY as an example, we demonstrate the difficulty of evaluating the effect of postrandomization events in clinical trials and discuss possible methodology...
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trialRenato D Lopes
Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 311, Terrace Level, Durham, NC 27705, USA
Eur Heart J 29:1827-33. 2008..The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS...
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromesSunil V Rao
The Duke Clinical Research Institute, Durham, NC 27705, USA
Am Heart J 155:369-74. 2008..We sought to determine the relationship between bleeding, blood transfusion, and measures of costs among patients with non-ST-segment elevation ACS...
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic TherapyRajendra H Mehta
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
Am J Med 124:48-57. 2011....
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention oManesh R Patel
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
J Am Coll Cardiol 61:651-8. 2013..The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care...
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparinMichael P Thomas
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA
J Thromb Thrombolysis 34:114-9. 2012..The required intensity of anticoagulation for benefit may be relatively modest when UFH is administered concomitantly with dual or triple platelet-directed therapy, particularly in patients undergoing early coronary revascularization...
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shockRajendra H Mehta
Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 99:793-6. 2007..This information may help physicians in deciding treatment options for patients with cardiogenic shock and counseling them about their risks...
Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuationL Kristin Newby
Duke Clinical Research Institute and the Duke Centers for Education and Research on Therapeutics CERTs, Durham, NC 27715 7969, USA
J Thromb Thrombolysis 16:119-28. 2003..While aspirin's secondary prevention benefit is clear, prior reports indicate that 19-83% of eligible patients may not use aspirin chronically...
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromesAbdallah G Rebeiz
Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27715, USA
Am J Med 116:119-29. 2004..We review the current evidence regarding the optimal integration of early antithrombotic and antiplatelet therapies with early coronary angiography and subsequent revascularization...
Statin use and sex-specific stroke outcomes in patients with vascular diseaseCheryl D Bushnell
Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
Stroke 37:1427-31. 2006..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
Long-term adherence to evidence-based secondary prevention therapies in coronary artery diseaseL Kristin Newby
Centers for Education and Research on Therapeutics, Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Circulation 113:203-12. 2006..Studies have examined the use of evidence-based therapies for coronary artery disease (CAD) in the short term and at hospital discharge, but few have evaluated long-term use...
Antidepressant use, depression, and survival in patients with heart failureCHRISTOPHER M O'CONNOR
Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt St, Box 3356, Durham, NC 27705, USA
Arch Intern Med 168:2232-7. 2008..Because depression has also been shown to be associated with increased mortality in these patients, it remains unclear if this association is attributable to the use of antidepressants or to depression...
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)Shelby D Reed
Center for Clinical and Genetic Economics, Durham, NC, USA
Am Heart J 148:122-8. 2004..In patients not taking ACE inhibitors, valsartan was economically attractive, increasing survival while reducing or marginally increasing overall costs...
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV)James M Yau
Duke University Medical Center, Durham, North Carolina, USA
Am J Cardiol 102:546-51. 2008..Further research is needed into the prevention and treatment of perioperative MI in patients undergoing CABG...
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgeryAbhinav Goyal
Duke Clinical Research Institute and Division of Cardiology, Duke University Medical Center, Durham, North Carolina 27710, USA
Ann Thorac Surg 83:993-1001. 2007..We investigated whether greater use of secondary prevention medications after coronary artery bypass graft surgery is associated with improved clinical outcomes...
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey
Duke Clinical Research Institute, Durham, NC 27715, USA
Int J Cardiol 139:123-33. 2010....
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgeryRajendra H Mehta
Duke Clinical Research Institute and Duke University Medical Center, Durham, NC 27715, USA
J Thorac Cardiovasc Surg 136:1149-55. 2008..Limited information exists on the impact of preoperative renal dysfunction on internal thoracic artery and saphenous vein graft failure and 2-year clinical outcomes in patients undergoing coronary artery bypass surgery...
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-IISana M Al-Khatib
Duke Clinical Research Institute, Durham, North Carolina 27715, USA
Ann Intern Med 142:593-600. 2005..However, in the range of survival benefit observed in MADIT-II, ICD therapy for these patients is economically attractive by conventional standards...
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overviewJohn L Petersen
Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 292:89-96. 2004..CONCLUSION: In a systematic overview of approximately 22 000 patients across the spectrum of ACS, enoxaparin is more effective than unfractionated heparin in preventing the combined end point of death or MI...
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarctionRajendra H Mehta
Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA, and Greenlane Cardiovascular Service, Auckland City Hospital, New Zealand
Eur Heart J 28:415-24. 2007..However, the relative prognostic importance of these measures over other baseline variables is less known...
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromesJohn H Alexander
Duke Clinical Research Institute, Durham, North Carolina 27710, USA
Am J Med 115:613-9. 2003..To investigate the prognostic importance of new small Q waves following an acute coronary syndrome...
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal functionChiara Melloni
Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 162:884-892.e1. 2011..Dose adjustment of renally excreted antithrombotic drugs is recommended for patients with reduced renal function. We examined the influence of dose modification on bleeding and efficacy...
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromesMatthew T Roe
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
Am Heart J 151:1205-13. 2006..We characterized guideline adherence for NSTE ACS by risk status...
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trialsKenneth W Mahaffey
Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA, and Catholic University Hospital, Leuven, Belgium
Eur Heart J 28:425-32. 2007..To assess the significance of creatine kinase (CK)-MB elevations in outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) who have undergone coronary artery bypass grafting (CABG) surgery...
Long-term clinical outcomes following coronary stentingKevin J Anstrom
Department of Biostatistics, Duke Clinical Research Institute, Durham, NC 27715, USA
Arch Intern Med 168:1647-55. 2008..The objective of this study was to compare the long-term clinical outcomes of patients receiving DES vs BMS in a clinical practice setting...
Safety and transparency of pediatric drug trialsDaniel K Benjamin
Department of Pediatrics, Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
Arch Pediatr Adolesc Med 163:1080-6. 2009....
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapyJeffrey S Berger
Duke Clinical Research Institute, Durham, NC, USA
Circulation 117:192-9. 2008..We therefore compared the acute mortality and bleeding risks associated with the initial use of 162 versus 325 mg aspirin in fibrinolytic-treated ST-elevation myocardial infarction patients...
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (ETracy Y Wang
Duke Clinical Research Institute, 2400 Pratt St, Durham, NC 27705, USA
Circulation 123:722-30. 2011..This analysis examines efficacy and safety of early eptifibatide in the setting of concurrent upstream clopidogrel use...
Influence of body mass index on the efficacy of revascularization in patients with coronary artery diseaseAslan T Turer
Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, NC 27710, USA
J Thorac Cardiovasc Surg 137:1468-74. 2009..We examined the effect of body mass index on the association between revascularization strategy and survival in patients with coronary artery disease...
Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge scoreCHRISTOPHER M O'CONNOR
Duke Clinical Research Institute, Duke University Medical Center, 2400 North Pratt Street, Box 3356, Durham, North Carolina 27705, USA
J Am Coll Cardiol 55:872-8. 2010..Identifying high-risk heart failure (HF) patients at hospital discharge may allow more effective triage to management strategies...
Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Svati H Shah
Duke University Medical Center, Durham, NC, USA
Am Heart J 160:371-379.e2. 2010..Clinical predictive models leave gaps in our ability to stratify cardiovascular risk. High-throughput molecular profiling promises to improve risk classification...
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trialJohn H Alexander
Duke University Medical Center, Duke Clinical Research Institute, Durham, NC 27715, USA
JAMA 294:2446-54. 2005..Edifoligide is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure...
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial)Melvin R Echols
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 99:315-21. 2007..African-American patients had significantly better adjusted 30-day outcomes but similar 6-month outcomes compared with white patients...
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIbRajendra H Mehta
Duke Clinical Research Institute, Duke University Medical Center, Box 17969, Durham, NC 27715, USA
Eur Heart J 29:880-7. 2008....
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Adrian F Hernandez
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 157:271-7. 2009..However, the effect of nesiritide on dyspnea at 6 or 24 hours is unknown, and no clinical outcome trials have been done to provide a reliable estimate of the effect of nesiritide on morbidity and mortality...
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) TrialSana M Al-Khatib
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA
Am Heart J 158:792-8. 2009..Current practice related to the management of atrial fibrillation (AF) complicating coronary artery bypass grafting (CABG) is uncertain...
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) TrialKent R Nilsson
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Heart 96:838-42. 2010..This study compared a rate control strategy to an anti-arrhythmic-based rhythm control strategy for the treatment of AF following myocardial infarction...
Rivaroxaban versus warfarin in nonvalvular atrial fibrillationManesh R Patel
Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
N Engl J Med 365:883-91. 2011..Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagulation than warfarin...
Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failureRajendra H Mehta
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA
Am J Cardiol 103:76-81. 2009..e., death and/or rehospitalization) in patients with HF in the design of treatment strategies for novel therapeutic agents in randomized controlled clinical trials...
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysisRajendra H Mehta
Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 27715, USA
J Am Coll Cardiol 57:138-46. 2011..The purpose of this study was to examine the association between lower socioeconomic status (SES), as ascertained by years of education, and outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI)...
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) TrialRobert M Califf
Duke Transitional Medicine Institute, Durham, NC 27715, USA
Am Heart J 156:623-32. 2008..The study was designed to evaluate whether reducing postprandial hyperglycemia, blockade of the renin-angiotensin-aldosterone system, or both interventions reduce the risk of T2DM or cardiovascular events in patients with IGT...
Outcomes of second revascularization procedures after stent implantationRichard P Konstance
Department of Medicine, Duke University Medical Center, Durham, NC, USA
J Med Syst 32:177-86. 2008..Further studies are needed to determine the optimum application for CABG vs. DES as a second or third revascularization procedure...
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic TrialRobert P Giugliano
TIMI Study Group, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 41:1251-60. 2003..The goal of this study was to evaluate combinations of eptifibatide with reduced-dose tenecteplase (TNK) in ST-elevation myocardial infarction (STEMI)...
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndromeSteve Leung
University of Kentucky, Lexington, KY, USA
Am Heart J 156:177-84. 2008..Smoking remains a major public health issue. We investigated the incidence of smoking and outcomes in high-risk patients with acute coronary syndromes. Differences in treatment effect of antithrombin therapies were also investigated...
Determining the most appropriate components for a composite clinical trial outcomeM Angelyn Bethel
Division of Endocrinology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
Am Heart J 156:633-40. 2008..This may not be true if the intervention has a lesser effect on some components of the composite. Consequently, treatment effect size may depend on the choice of composite...
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)Emmanouil S Brilakis
Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Am J Cardiol 102:552-8. 2008..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or bothL Michael Prisant
Hypertension and Clinical Pharmacology, Medical College of Georgia, Augusta, Georgia 30912, USA
J Am Coll Cardiol 51:1865-71. 2008....
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trialMarino Labinaz
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Circulation 105:322-7. 2002..The treatment effect of eptifibatide in the prior CABG group was similar to the effect seen in patients without prior CABG...
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
JAMA 288:2130-5. 2002..Rates of nonfatal ischemic complications were significantly diminished...
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)Debabrata Mukherjee
University of Michigan Health System, Ann Arbor, Mich, USA
Am Heart J 144:995-1002. 2002..These findings support the rationale and promise for combining GP IIb/IIIa blockers and LMWH for future management of acute coronary syndrome...
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin Arno Breeman
Thorax Center, Erasmus University Medical Center, Rotterdam, The Netherlands
Cardiology 98:195-201. 2002..CONCLUSIONS: The observed differences in clinical outcomes are explained by an imbalance in baseline characteristics and comorbid conditions between the analyzed groups of patients...
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and CanadaWayne B Batchelor
Heart and Vascular Institute, Tallahassee Memorial Healthcare, Tallahassee, FL, USA
Am Heart J 145:349-55. 2003....
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular diseaseEric J Topol
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Circulation 108:399-406. 2003....
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)Thaddeus R Tolleson
Duke Clinical Research Institute, Durham, North Carolina, USA
Am J Cardiol 92:330-3. 2003..These patients and their outcomes may be more representative of patients with typical acute coronary syndromes undergoing stenting in clinical practice...
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothMarc A Pfeffer
Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
N Engl J Med 349:1893-906. 2003..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm
Cleveland Clinic Foundation, Cleveland, Ohio, USA
J Am Coll Cardiol 43:542-8. 2004..Although combination therapy did not provide a survival benefit, nonfatal ischemic outcomes, including reinfarction, recurrent ischemia, and urgent revascularization, were substantially reduced...
International differences in evolution of early discharge after acute myocardial infarctionPadma Kaul
University of Alberta, Edmonton, Alberta, Canada
Lancet 363:511-7. 2004..We aimed to identify the extent to which countries have taken advantage of the opportunity for early discharge...
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarctionC Michael Gibson
Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
J Am Coll Cardiol 43:1170-6. 2004....
